{"name":"Iovance Biotherapeutics","slug":"iovance","ticker":"IOVA","exchange":"NASDAQ","domain":"iovance.com","description":"Iovance Biotherapeutics, Inc. is a biopharmaceutical startup based in San Carlos, California. The company works to develop tumor-infiltrating lymphocyte (TIL) therapies against cancer.","hq":"San Carlos, CA","founded":2007,"employees":"975","ceo":"Frederick Vogt","sector":"Cell Therapy / Immuno-Oncology","stockPrice":3.33,"stockChange":0.01,"stockChangePercent":0.3,"marketCap":"$1.4B","metrics":{"revenue":263502000,"revenueGrowth":17.7,"grossMargin":34.3,"rdSpend":300270000,"netIncome":-390978000,"cash":163078000,"dividendYield":0,"peRatio":-13.8,"fiscalYear":"FY2018"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"Lifileucel plus Pembrolizumab","genericName":"Lifileucel plus Pembrolizumab","slug":"lifileucel-plus-pembrolizumab","indication":"Metastatic melanoma (Phase 3 development)","status":"phase_3"},{"name":"Pembrolizumab with Optional Crossover Period","genericName":"Pembrolizumab with Optional Crossover Period","slug":"pembrolizumab-with-optional-crossover-period","indication":"Melanoma (advanced or metastatic)","status":"phase_3"}]}],"pipeline":[{"name":"Lifileucel plus Pembrolizumab","genericName":"Lifileucel plus Pembrolizumab","slug":"lifileucel-plus-pembrolizumab","phase":"phase_3","mechanism":"Lifileucel is an autologous tumor-infiltrating lymphocyte (TIL) therapy that expands patient-derived T cells from their tumor and reinfuses them alongside pembrolizumab, a PD-1 inhibitor, to enhance anti-tumor immune response.","indications":["Metastatic melanoma (Phase 3 development)"],"catalyst":""},{"name":"Pembrolizumab with Optional Crossover Period","genericName":"Pembrolizumab with Optional Crossover Period","slug":"pembrolizumab-with-optional-crossover-period","phase":"phase_3","mechanism":"Pembrolizumab blocks PD-1 on immune cells to release the brakes on anti-tumor immunity, allowing T cells to recognize and attack cancer cells.","indications":["Melanoma (advanced or metastatic)","Non-small cell lung cancer (advanced or metastatic)","Head and neck squamous cell carcinoma","Hodgkin lymphoma (relapsed or refractory)","Urothelial carcinoma (advanced or metastatic)"],"catalyst":""}],"recentEvents":[{"date":"2023-02-23","type":"regulatory","headline":"Iovance Biotherapeutics Announces FDA Approval of Lifileucel for Metastatic or Locally Advanced Melanoma","summary":"The FDA approved lifileucel for the treatment of adult patients with metastatic or locally advanced melanoma who have not responded to other treatments.","drugName":"lifileucel","sentiment":"positive"},{"date":"2022-11-09","type":"earnings","headline":"Iovance Biotherapeutics Reports Third Quarter 2022 Financial Results","summary":"The company reported a net loss of $44.4 million for the third quarter of 2022.","drugName":"","sentiment":"neutral"},{"date":"2022-08-10","type":"deal","headline":"Iovance Biotherapeutics Announces Collaboration with Bristol Myers Squibb to Develop and Commercialize TIL Therapies","summary":"The collaboration aims to develop and commercialize TIL therapies for various types of cancer.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxPc3o3WHpBS1NjN28zOUh5aEdlQjl4cmNOWjVoT2g0ZEx3SC0zRUNjZTZsanZ0SUpOOHNUNjMzbEY0YkVSZGpHcjBrZVhlaU42eENFek1jQW5kY1JabHdkR05mN2pEbGJRTWZlN2Zham1CX3ZDNzRuZWZVclcxM2YzUjVpX3hmZm5w?oc=5","date":"2026-04-07","type":"pipeline","source":"PHILADELPHIA.Today","summary":"Iovance’s Philadelphia Facility Transforms Immune Cells Into Lifesaving Melanoma Therapy - PHILADELPHIA.Today","headline":"Iovance’s Philadelphia Facility Transforms Immune Cells Into Lifesaving Melanoma Therapy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwFBVV95cUxOU0dEOHZCLWtoV241VDNvN1lUc3IxbURhVnl0QWdpenU2ZnA3Y3UwcDc4dk1LT3ctTG42eDd0SXdVZzZUb3psbDN4aldYYWdpaC1DdXd4QzJybHpWU1JoMmtxZXNJcEZpd0xBbWlFaE5nLW5hLU5idHFyMkFOUXo1dExJWXBqaEQweC1DOTNQcXRyMVd5NlhLSDdJeDY1aDNHSTRVanE0YWIwZzQzMVNvdUdLZEliT2s?oc=5","date":"2026-03-30","type":"pipeline","source":"Fierce Pharma","summary":"BMS, Novartis, Gilead, Iovance dinged over biologics promos in rare spate of CBER untitled letters - Fierce Pharma","headline":"BMS, Novartis, Gilead, Iovance dinged over biologics promos in rare spate of CBER untitled letters","sentiment":"neutral"},{"date":"2026-03-20","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirgFBVV95cUxOajB1MHV1YjRkbFNJSllDUEZrN19WQ1hxenoyRE5rWkVzWGk2TzJ5RVNqU2ZuNFNRS3V3UjJ4ZWZ4eFZ6dG5Jb0ZUU1J5V1NZc1huZWFiLVdjZU5XNW9uNVBuNVdQQU5KbW9ZcTVXaUljc3g5cWlwbXdCMGhJSFhBOUVSZmpVbzJ1bE1QLUxwM2pKd2NqU0RZMTNRTHQ3MzcwWWNScmN0dmNWb0tXM1E?oc=5","date":"2026-03-04","type":"pipeline","source":"Seeking Alpha","summary":"Iovance Biotherapeutics: Short-Term Pain, Long-Term Gain - I'm Still Bullish After All These Years - Seeking Alpha","headline":"Iovance Biotherapeutics: Short-Term Pain, Long-Term Gain - I'm Still Bullish After All These Years","sentiment":"neutral"},{"date":"2026-02-24","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-02-24","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwgFBVV95cUxPQlVIUlJxNVhaN1ZYMTZwRXlWWVlfemdNZXltQ0dZLWktZFJyQUdOVzBELTlVSkt6SXFSU2hnNlRFcHVuWWtTM3REYTl1WjN2MVhJVUNVZjlqVWlLVUhHMzBOTW5yMnVYX0pEa1JKWW1ya3piamJjZl9ac0dMVG9OS3F4QnJjaWltX1QxeHJGNzl1aF90azNialM2OFVHWWR2T1FzdUhnWnBOdmdNOFZZakxabE8wRk03MFBPMDZDU0x0Zw?oc=5","date":"2026-01-02","type":"pipeline","source":"AD HOC NEWS","summary":"Iovance Biotherapeutics Stock: Sleepy Now, But Could This Cancer Play Go Viral Next? - AD HOC NEWS","headline":"Iovance Biotherapeutics Stock: Sleepy Now, But Could This Cancer Play Go Viral Next?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxOZDZON3pNd2RvNTNrbll6Z2pHQl9sTTB6eFpZbUp2dk8xN1N3OFN5enMwbWdlcVlNMm04U3VqTG9RaEQ3eXI0eDNRblZwaEpyUFprQ01KVXZkelhVZi1hdkJReDBFVEkwdVcyb0VDeks2c2lURkVXLWRjaGpZUWt2UGNjcUs5QU9TcVRjNl94bXlHbXY2Yjh5STMyMmNQbDhZLUFtNkR4blJTa0M0S1c0S1Z2dy1ndw?oc=5","date":"2025-12-29","type":"pipeline","source":"Seeking Alpha","summary":"Iovance Biotherapeutics: Bright Prospects For 2026 (NASDAQ:IOVA) - Seeking Alpha","headline":"Iovance Biotherapeutics: Bright Prospects For 2026 (NASDAQ:IOVA)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxNamk5Y0dFcDBLZjZ0VjUxcjJ2aTUxUEJBak9pVWdYcnZxbG53YTBaRGc3Yzl4MG5lSDJFRW9INWVHTkRXeVRCZ1pfb2pGWGJuZGs1c29Oa0xubDZUVFF1YzViN0puY0ctSXhPMGVZR2VSWWdIbXQwTFBOWHVXdEdCeHdnRUVMLUtwY1NQaXQxR1cweE0tMGc3cg?oc=5","date":"2025-12-07","type":"pipeline","source":"The Motley Fool","summary":"2 Stocks That Could Soar by 52% and 282%, According to Wall Street - The Motley Fool","headline":"2 Stocks That Could Soar by 52% and 282%, According to Wall Street","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxQLU9od1g0ZWxOUWxfcUpRV0VFb185c0JQUTJVOEliclJ1Sm1PNS1EMjFlRDZsUmtBZWo3REdXbUhWWTEzZjFlUEI4RV9jZzNBaEdjeUpTdzRsRmNfclJDZENULVAtS2JuS1ZiS2pqZDh0REt1bnZsLWJXanJFN2k2bjRmUUpkb3R1RjVTMl8zOHVoTzJtaVE?oc=5","date":"2025-11-11","type":"pipeline","source":"The Motley Fool","summary":"Down 75% in 12 Months, Can Iovance Biotherapeutics Stock Turn Things Around? - The Motley Fool","headline":"Down 75% in 12 Months, Can Iovance Biotherapeutics Stock Turn Things Around?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxQeEJSc0lKOS1RT09MWER6SThmeUVnbUY5M1lMN1VaN0NGeUxXX1pyUExzUWNZUWpIV0QwSzIxQk1fS1BaTjRCQnY3dWFhQ1hjZXpVanFNbzF0NGdQRDQyb01Ia1dGQ1BVa2V1RGQ5T1dTc1U3eGtqc2tJeExaZ1U4SFdfVGlTWkhqVElz?oc=5","date":"2025-11-06","type":"pipeline","source":"timothysykes.com","summary":"Iovance Biotherapeutics Surge: Exploring Recent Developments - timothysykes.com","headline":"Iovance Biotherapeutics Surge: Exploring Recent Developments","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiggFBVV95cUxQdkg1dVpBVEQyRllfR1BKdGRlc3NxU3JMTUplU2RReFJsUnZIMVFpTmh3Q1ZvbDFjdWMyZG4wdzZIRGNDVVZuM2MwMHBVVHd0cFZxV3dLdml6SlVHUXVKYmtnRFRXai1rOGJMal9QTDRIVjhnV082WG5lcEx1bkpPcWp3?oc=5","date":"2025-08-08","type":"pipeline","source":"The Pharma Letter","summary":"Iovance Bio updates on Amtagvi - The Pharma Letter","headline":"Iovance Bio updates on Amtagvi","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxPNVVRdHV5NTRzYW5BeG9xMDRsTmpGdEMxN0tlYjF1TWtDemdwUnRhN1MzQ0lyX01jbnZwX3Zaei16dU9HaGR3cjJfYlVscWJQWUFfdXZhWFJDRFA0UTM1cEdXYmZvd3huOHh4TF9sb2pfbHZPenJNVDJFMjBxU0Q2VVVNdzhhamdRaUZvRzZIZGk1LUI5Y2x2TzN2Zw?oc=5","date":"2025-08-07","type":"pipeline","source":"BioPharma Dive","summary":"Iovance cuts staff amid slow sales start for ‘TIL’ cell therapy - BioPharma Dive","headline":"Iovance cuts staff amid slow sales start for ‘TIL’ cell therapy","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-07-22","type":"deal","source":"simplywall.st","summary":"Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Shares Fly 26% But Investors Aren't Buying For Growth - simplywall.st","headline":"Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Shares Fly 26% But Investors Aren't Buying For Growth","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijwFBVV95cUxPTFRoM3RfLXhTdnlvUGF0SWljZDFEMnNYdDZKSndYYWgtd0xLRlpiWGIyREh2aFltMm9yVTFrTE90eXA0NDVMVWlDZWF0OFhKVnJQWXBSMjYza1JxTlBFNDFRLTdObWR6SnpwMm5xRjJQZjE5X0FLYV8wbzlaOXFfcktXMGhYYTVYY3BvTmlVMA?oc=5","date":"2025-05-09","type":"pipeline","source":"Barron's","summary":"Iovance Biotherapeutics Stock Sinks 46%. Here’s Why the Biotech Is Tumbling. - Barron's","headline":"Iovance Biotherapeutics Stock Sinks 46%. Here’s Why the Biotech Is Tumbling. - Barron's","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_3":2},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Bristol Myers Squibb","Merck & Co.","Roche Holding"],"therapeuticFocus":["Cancer Immunotherapy","Tumor-Infiltrating Lymphocyte (TIL) Therapy"],"financials":{"source":"sec_edgar","revenue":0,"revenuePeriod":"2018-12-31","revenueHistory":[{"value":0,"period":"2018-12-31"},{"value":0,"period":"2018-09-30"},{"value":0,"period":"2018-06-30"},{"value":0,"period":"2018-03-31"},{"value":0,"period":"2017-12-31"},{"value":0,"period":"2017-09-30"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":300270000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-390978000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":163078000,"cashHistory":[],"totalAssets":913170000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":3.33,"previousClose":3.32,"fiftyTwoWeekHigh":5.63,"fiftyTwoWeekLow":1.64,"fiftyTwoWeekRange":"1.64 - 5.63","fiftyDayAverage":3.41,"twoHundredDayAverage":2.6,"beta":0.76,"enterpriseValue":1120178560,"forwardPE":-13.8,"priceToBook":1.97,"priceToSales":5.21,"enterpriseToRevenue":4.25,"enterpriseToEbitda":-3.09,"pegRatio":0,"ebitda":-362273984,"ebitdaMargin":-137.5,"freeCashflow":-162422128,"operatingCashflow":-302408000,"totalDebt":49444000,"debtToEquity":7.1,"currentRatio":3.2,"returnOnAssets":-27.3,"returnOnEquity":-55.5,"analystRating":"","recommendationKey":"none","numberOfAnalysts":10,"targetMeanPrice":9,"targetHighPrice":16,"targetLowPrice":4,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":0.4,"institutionHeldPercent":71,"sharesOutstanding":411961607,"floatShares":353409504,"sharesShort":115070206,"shortRatio":5.24,"shortPercentOfFloat":27.9,"epsTrailing":-1.09,"epsForward":-0.24,"revenuePerShare":0.74,"bookValue":1.7,"officers":[{"age":51,"name":"Dr. Frederick G. Vogt Esq., J.D., Ph.D.","title":"Interim CEO, President, General Counsel, Corporate Secretary & Director"},{"age":52,"name":"Dr. Igor P. Bilinsky Ph.D.","title":"Chief Operating Officer"},{"age":58,"name":"Dr. Friedrich  Graf Finckenstein M.D.","title":"Chief Medical Officer"},{"age":69,"name":"Dr. Raj K. Puri M.D., Ph.D.","title":"Chief Regulatory Officer"},{"age":59,"name":"Ms. Corleen M. Roche","title":"Chief Financial Officer"},{"age":53,"name":"Mr. Matthew W. Rosinack","title":"Principal Accounting Officer"},{"age":null,"name":"Ms. Sara  Pellegrino","title":"Senior Vice President of Investor Relations & Corporate Communications"},{"age":null,"name":"Ms. Tracy  Winton","title":"Executive Vice President of Human Resources"}],"industry":"Biotechnology","irWebsite":"","website":"https://www.iovance.com","phone":"650 260 7120"}}